Close Menu

NEW YORK (GenomeWeb) – Courtagen Life Sciences reported today that it has completed the comprehensive Clinical Laboratory Evaluation Program and has received its clinical laboratory permit form the state of New York.

Courtagen — a CLIA/CAP certified company — creates tests for the diagnosis of neurological disorders, primarily using next-generation DNA sequencing, bioinformatics, and clinical interpretation. These tests are designed to help physicians reveal the linkages between the genotypes and phenotypes of various neurological diseases, the company said in a statement.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News writes that viral genomic surveillance in the US faces systemic issues.

President Joe Biden is seeking an increase in federal spending, including higher budgets for the National Institutes of Health and Centers for Disease Control and Prevention.

A small, early-stage trial of a combination therapy for brain cancer reports favorable responses in two patients, according to the Guardian.

In PLOS this week: sex-stratified genome-wide association study of chronic pain, sequencing data from Indigenous Mexican groups, and more.